Items Tagged ‘parp’

October 20th, 2016

Tesaro Provides Real Benefit to Ovarian Cancer Patients

By

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the […]

View full entry

Tags: 2016, BRCA mutation, ESMO, News, niraparib, Ovarian Cancer, parp, poly(ADP)-ribose polymerase, recurrent, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer, Tesaro


December 29th, 2014

Lynparza Approved in Advanced Ovarian Cancer

By

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes. According to statistics from the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. The ACS […]

View full entry

Tags: brca, lynparza, News, olaparib, Ovarian Cancer, parp, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer